Ilene Galinsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ilene Galinsky has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Daniel J. DeAngelo
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
60 shared publications - Richard M. Stone
Dana-Farber Cancer Institute, Boston, MA, USA
58 shared publications - Donna Neuberg
Department of Data Science, Dana-Farber Cancer Institute, Boston, USA
47 shared publications - Eric S. Winer
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
47 shared publications - Evan C. Chen
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
47 shared publications - Jacqueline S. Garcia
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
47 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S8 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S6 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S7: Reasons for study discontinuation.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S7: Reasons for study discontinuation.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S5 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S1: Study representativeness table.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S1: Study representativeness table.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S2: Treatment dose-levels. For cycle 1, venetoclax dosing followed a ramp-up from days 1 to 3 and navitoclax dosing began on day 3 only if platelets remained ≥10 × 109/L (platelet transfusions allowed thereafter).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S2: Treatment dose-levels. For cycle 1, venetoclax dosing followed a ramp-up from days 1 to 3 and navitoclax dosing began on day 3 only if platelets remained ≥10 × 109/L (platelet transfusions allowed thereafter).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S3: Patient-by-patient characteristics.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Table S3: Patient-by-patient characteristics.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine
Figure S2 from Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine